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Abstract A high level of adherence to antiretroviral
treatment is essential for optimal clinical outcomes in HIV
infection, but measuring adherence is difficult. We inves-
tigated whether responses to a questionnaire eliciting
caregiver beliefs in medicines were associated with
adherence of their child (median age 2.8 years), and whe-
ther this in turn was associated with viral suppression. We
used the validated beliefs in medicine questionnaire
(BMQ) to measure caregiver beliefs, and medication event
monitoring system caps to measure adherence. We found
significant associations between BMQ scores and adher-
ence, and between adherence and viral suppression. Among
children initiating Antiretroviral therapy (ART), we also
found significant associations between BMQ ‘necessity’
scores, and BMQ ‘necessity-concerns’ scores, and later
viral suppression. This suggests that the BMQ may be a
valuable tool when used alongside other adherence mea-
sures, and that it remains important to keep caregivers well
informed about the long-term necessity of their child’s
ART.
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Introduction
The treatment of HIV with antiretroviral drugs requires
good adherence, which can be challenging for children and
caregivers in low-income countries [1, 2]. Known barriers
include transport to clinics and long waiting times once
there, while food insecurity, caregiver illness and elderly
non-parent caregivers can pose additional problems [3–6].
Suggested ways to improve adherence include the use of
peer counsellors, patient-selected treatment supporters,
family focused treatment, and financial support for food
and transport [7–10]. However, the feasibility and sus-
tainability of these measures is often limited.
Despite the problems, high levels of antiretroviral ther-
apy (ART) adherence have been reported among patients in
sub-Saharan Africa, sometimes higher than those in high-
income countries such as the United States of America
[11, 12]. Self-reported adherence levels among patients
purchasing ART in Kampala were comparable with those
found in a high-income country [13]. The challenge is
therefore to identify patient groups most likely to have poor
adherence, and, particularly to identify caregivers whose
children may be at risk of poor adherence given that HIV-
infected children will need to take ART for life.
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The monitoring of adherence by clinics is difficult. The
CHAPAS-1 study compared caregiver report, pill counts,
Medication Event Monitoring System (MEMS) caps and a
visual analogue scale, finding that only adherence as
measured by MEMS caps was significantly associated with
viral suppression [14]. Unfortunately, while MEMS caps
may provide the most precise measure of adherence, they
are also expensive and sometimes considered intrusive
[15, 16].
The ‘necessity-concerns’ framework has been proposed
as a model for understanding patients’ perspectives on
ART, and hence for predicting treatment uptake and
adherence to treatment once started [17, 18]. Experience in
a variety of disease areas has shown that factors affecting
patients’ medication decisions fall into two categories:
perceptions of ‘necessity’ for treatment, and ‘concerns’ of
potential adverse effects that might include long term
toxicity or lifestyle disruption [19]. The Beliefs about
Medicines Questionnaire (BMQ) is a validated tool that
separately measures ‘necessity’ and ‘concern’ [20].
Patients with strong beliefs in ‘necessity’ are likely to have
higher treatment adherence, while those with strong ‘con-
cerns’ are at risk of lower adherence. By combining the
two measures in a ‘necessity-concerns’ score, a single
score is produced that balances the opposing tensions
within each patient. We used the BMQ to measure the
children’s caregivers beliefs about medication prescribed
for their children in this study.
In this study we investigated two hypotheses: (1) that
caregiver beliefs in medicine were associated with their
child’s adherence; (2) that adherence was associated with
subsequent virological outcomes. If supportive evidence
was found for both these hypotheses it may suggest that the
BMQ is a feasible method for clinics to identify children at
risk of treatment failure because of poor adherence, and
enable support to be targeted appropriately and efficiently.
Methods
This study was part of the CHAPAS-3 randomised con-
trolled clinical trial; it was a sub-study planned at the start
of the main trial (ISRCTN Trial Registry number,
69078957).
Main Study
The CHAPAS-3 trial was an open-label, parallel-group
randomised trial comparing three nucleoside reverse tran-
scriptase inhibitors (NRTIs) in first-line treatment of HIV-
infected African children in three centres in Uganda and
one in Zambia (2010–2014). 478 children were randomised
to receive stavudine (d4T), zidovudine (ZDV) or abacavir
(ABC), together with lamivudine (3TC) and either efavir-
enz (EFV) or nevirapine (NVP). Drugs were provided as
dual-NRTI plus single non-NRTI (NNRTI), or as triple
drug scored tablet ‘mini-pill’ formulations. Children were
ART naı¨ve or ART experienced (on ART for more than
2 years with viral load\50 copies/ml); follow-up was for
at least 96 weeks. The primary endpoint was grade 2/3/4
clinical or grade 3/4 laboratory adverse events with effi-
cacy as measured by viral load suppression being a sec-
ondary outcome (Grading of adverse events: grade (1)
mild, no intervention; grade (2) moderate, minimal inter-
vention; grade (3) severe, hospitalisation indicated; grade
(4) potentially life-threatening, urgent intervention indi-
cated). The trial results showed no difference in toxicity or
efficacy between the three NRTIs, but endorsed the WHO
2013 guidelines recommendation of once daily ABC-con-
taining regimen for African children due to absence of
hypersensitivity and superior resistance profile [21].
Adherence Substudy
The substudy aimed to investigate whether caregiver’s
views on medicines prescribed for their children affected
adherence to ART given to the child, and ultimately their
treatment outcome. The BMQ was used to measure care-
givers attitudes towards their child’s treatment, adherence
was measured using MEMs caps and HIV-1 viral load
assayed with Roche COBAS Ampliprep/Taqman v2.0.
The BMQ is an 18-item validated instrument, with ten
specific questions measuring beliefs about the actual
medicines being prescribed to the patient (here modified to
relate to the caregiver’s child), and eight questions of wider
scope that measure general beliefs about all medicine
[17–20]. Five of the specific questions are used to calculate
the ‘necessity’ score and the other five used to calculate the
‘concern’ score. The ‘necessity-concern’ score therefore
derives from the specific questions and directly relates to
medicine currently prescribed. Four of the general ques-
tions are used to calculate a score measuring beliefs in the
‘overuse’ of medicine and the other four to calculate a
score on ‘perceived harm’ done by medicine. Two further
questions were added, of interest in CHAPAS-3, eliciting
information on treatment side effects and on whether
divine healing was considered more important than medi-
cine. Scoring of the questionnaires is described in supple-
mentary material 1.
MEMS caps record the date/time of every pill bottle
opening using an electronic chip contained in the cap. In
CHAPAS-3, children used MEMS caps during weeks 0–18
and weeks 54–72, with caps rotating between different
children as the study progressed. Adherence data was thus
collected for a child’s first 4 months in the study (start of
treatment for ART naı¨ve), and for another 4 months
AIDS Behav
123
starting at 1 year. The calculation of adherence from
MEMS data is described in supplementary material 2.
Statistical Analysis
ART naı¨ve and ART experienced children were analysed
separately since ART experienced children were expected
to have good adherence, all having been on treatment for at
least 2 years and with suppressed viral load. Analysis was
also conducted separately for the first four-month period
(Period 1), and the 4 months starting at 1 year (Period 2),
this was to investigate behaviour at the time children ini-
tiated treatment, and then to see if any changes had
occurred after 1 year’s experience of treatment. BMQ and
MEMS data were used to examine our first hypothesis that
caregiver beliefs in medicine were associated with their
child’s adherence, while MEMS data and viral load were
used to examine our second hypothesis that adherence was
associated with subsequent virological outcomes. Analysis
of Period 1 included children with MEMS data in weeks
0–18, BMQ data at week 0, 6 or 24, and viral load mea-
sured at week 48. Analysis of Period 2 included children
with MEMS data in weeks 54–72, BMQ data at week 48 or
72, and viral load measured at week 96. The lower limit of
detection for viral load assays was 100 copies/ml because
these assays were run retrospectively and many samples
had low volumes and therefore had to be diluted.
Univariate associations were investigated between BMQ
scores, MEMS adherence and viral load with baseline (trial
enrolment) covariates including age, sex, relation to pri-
mary carer, treatment arm, CD4 % and weight-for-age
Z-score (WAZ).
Multivariate repeated-measures regression models were
used to explore the association between BMQ and MEMS,
between MEMS and VL, and between BMQ and VL.
Linear regression models were used for continuous out-
comes of BMQ and MEMS, logistic models for the binary
outcome of VL suppression. These models were adjusted
for baseline covariates where a significant univariate
association (p\ 0.05) had been identified with either
BMQ, MEMS or VL.
Results
In Period 1, 271 (74 %) ART naı¨ve and 97 (86 %) ART
experienced children with BMQ, MEMS and viral load
data were included in the analysis (Table 1). Among ART
naı¨ve children, median age was 2.8 years, 53 % were male,
median CD4 % was 20 and 49 % had WHO stage 3/4
disease. ART experienced children were older with signs of
CD4 recovery after median 3.5 years treatment; their
median age was 6.2 years and median CD4 % was 35 %.
Demographic and disease characteristics were similar to
those of the overall CHAPAS-3 population [21]. Analysis
of Period 2 included 235 ART-naı¨ve and 98 ART-experi-
enced children, 70 and 88 % of those in follow-up
respectively. Missing data were primarily due to MEMS
cap failures, meaning there were insufficient caps available
for all children in the study in each time period. MEMS cap
failures appeared to occur at random.
Descriptive Summary of BMQ, MEMS and Viral
Load Data
Responses to the BMQ indicated a positive overall attitude
among caregivers towards treatment (Table 2). Strong beliefs
in the necessity of treatment were expressed with a median
score of 20 (IQR 19.3,21.7, possible range 5–25). Beliefs in
necessity considerably outweighed concerns about treatment,
giving highly positive ‘necessity-concern’ differential scores
(ART naı¨ve Period 1, median = 8.3, IQR 6.7–9.7). For the
‘general’ belief scales, overuse and harm, carers on average
had neutral views about overuse, but expressed some dis-
agreement with statements that medicines caused harm. For
these scales the mid-point was 12, median overuse score was
12.3 among ART naı¨ve in Period 1 (IQR 11, 13.7). Some
positive change in scoreswas alsoobservedbetweenPeriods 1
and 2, particularly among those ART naı¨ve at enrolment,
belief in necessity increased while concern reduced, increas-
ing further the necessity-concern differential (median = 8.3
vs. 10.0 in Periods 1 and 2 respectively, p\ 0.001).
MEMS data indicated a high level of adherence to
treatment, on average over 90 % of doses were taken
among ART naı¨ve and experienced groups in Periods 1 and
2 (Table 2). Observed viral load suppression was consis-
tent with good adherence to treatment, 69 % of children
ART naı¨ve at enrolment were suppressed\100 copies/ml
by week 48, 93 % of ART experienced children remained
suppressed. Corresponding figures in Period 2 (VL at week
96) were 74 and 96 % of ART naive and experienced
children respectively. Some positive change was again seen
between Periods 1 and 2 in those ART naı¨ve at enrolment,
with higher adherence in Period 2 (92 vs. 96.5 % in Periods
1 and 2 respectively, p = 0.006), although a small decline
in adherence was observed in the ART experienced group.
Statistically significant (p\ 0.05) associations were
observed between several baseline demographic and dis-
ease-related covariates, and either BMQ necessity-concern
scores, MEMS adherence or viral suppression in Period 1
(Table 3). Among ART-naı¨ve children, increased viral
suppression was observed in girls, older children and those
with higher WAZ. BMQ scores were associated with both
WHO stage and CD4 %, while MEMS adherence was
better in children with high WAZ. Both BMQ scores and
MEMS adherence also differed between centres. Since all
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covariates showed some association with BMQ scores,
MEMS adherence or viral suppression, multivariate models
were adjusted for all the factors considered.
BMQ and MEMS Adherence (Hypothesis 1)
High BMQ necessity-concern scores were significantly
associated with better adherence in ART-naı¨ve children
(Table 4); in Period 1a difference of ?1 point in necessity-
concern was associated with a 0.33 % increase in adher-
ence (p = 0.002). No significant association was observed
between BMQ harm and overuse scores and adherence.
Some evidence of poorer adherence was seen among ART-
naı¨ve children whose carers reported side effects of treat-
ment (p = 0.09), while significantly worse adherence was
observed in Period 2 among ART naı¨ve children whose
carers believed in divine healing (p = 0.008).
MEMS Adherence and VL Suppression (Hypothesis 2)
A significant association was observed between treatment
adherence and viral suppression among children ART-
naı¨ve at enrolment (Table 5). In Period 2, each 1 % higher
adherence was associated with a 5 % increase in the odds
of suppression (p = 0.006), while a smaller marginally
significant increase was seen in Period 1 (p = 0.07). No
association was seen between adherence and viral
suppression in ART experienced children, but all children
were suppressed at enrolment and nearly all remained
suppressed at weeks 48 and 96.
BMQ and Viral Suppression
Having found significant associations supporting hypothe-
ses 1 and 2, we analysed the direct association between
BMQ and viral suppression. A statistically significant
association was observed between viral suppression and
high BMQ necessity scores among ART-naı¨ve children in
Period 2 (p = 0.03), while in the same group the associa-
tion between viral suppression and high necessity-concern
difference scores was of marginal significance (p = 0.06;
Fig. 1; Supplementary material 3). Most other associations
between viral suppression and BMQ scores were not sta-
tistically significant, although there was evidence that in
ART-naı¨ve children, early suppression was less likely in
children whose caregivers had greater concerns about
medication (p = 0.03).
Discussion
We observed significant associations between caregiver
beliefs in medicine and their children’s adherence to
treatment; children had better adherence if their caregiver’s
Table 1 Follow-up and
demographic characteristics
Naive at enrolment Experienced at enrolment
Period 1 (n = 365) (n = 113)
Children in follow-up 365 (100%) 113 (100%)
With MEMS, BMQ and VL 271 (74)% 97 (86)%
Baseline characteristics n = 271 n = 97
Age, years 2.8 (1.6,3.9) 6.2 (5.5–7.2)
Sex, male 144 (53%) 49 (51%)
WHO stage
1 32 (12%) 24 (25%)
2 105 (39%) 20 (21%)
3 115 (42%) 36 (37%)
4 19 (7%) 17 (18%)
CD4% 20% (13–25%) 35% (30–39%)
Weight-for-age Z -1.9 (-3.0 to -0.9) -1.1 (-1.7 to -0.3)
Primary carer, mother 201 (74%) 59 (61)%
Treatment arm
D4T 99 (37%) 28 (29%)
ZDV 79 (29%) 39 (40%)
ABC 93 (34%) 30 (31%)
Period 2
Children in follow-up 335 (100%) 112 (100%)
With MEMS, BMQ and VL 235 (70%) 98 (88%)
Numbers show n (%) or median (IQR)
AIDS Behav
123
belief in the necessity of medicine outweighed concern.
We also observed significant associations between adher-
ence measured by MEMS and suppression of viral load,
confirming the results of the CHAPAS-1 study [14]. We
also found some evidence of a direct association between
BMQ necessity/necessity-concerns and viral load, although
only in the second period, power to detect such an asso-
ciation being low. Further, in the initial period on ART,
beliefs about overuse of medication appeared more
important for viral load suppression, potentially indicating
different underlying drivers of early vs later adherence in
caregivers of HIV-infected children, and thus suggesting
that different behaviour change techniques may need to be
employed to optimise adherence and viral load response at
different stages on ART.
Evidence of associations was stronger in the ART naı¨ve
group. The ART naı¨ve group was larger than the ART
experienced, so power to detect associations was higher,
but the experienced children were also likely to be a more
homogenous group, since the eligibility criteria requiring
[2 years on ART with viral load \50 copies/ml at
screening probably excluded children with poor adherence.
Results were broadly similar in Periods 1 and 2. This was
perhaps expected in the ART experienced group where
entry to the trial represented little change. For the ART
naı¨ve, this was encouraging since long term adherence can
present problems with reduced motivation to treat children
regularly once their condition improves on ART [22].
The responses to the beliefs in medicine questionnaire
revealed a positive overall attitude towards medicines. The
necessity and concern scales, measuring attitude towards
medicine in general, showed that belief in the necessity of
medicines strongly outweighed concern about their use.
Particularly encouraging was the increasingly positive
Table 2 Descriptive statistics
Naive at enrolment Experienced at enrolment
Period 1 (n = 271) (n = 97)
BMQ
Necessitya 20.0 (19.3–21.7) 21.0 (20.0–22.3)
Concerna 12.0 (10.7–14.7) 11.7 (10.3–13.7)
Necessity-concernb 8.3 (6.7–9.7) 9.3 (7.3–10.7)
Overusec 12.3 (11.0–13.7) 11.3 (10.3–13.0)
Harmc 10.0 (9.0–11.0) 9.3 (8.3–10.7)
MEMS
Days with data 127 (125–127) 127 (127–127)
Adherence 92.0% (83.9–96.0%) 94.9% (87.4–98.4%)
VL
\100 copies/ml 186 (69%) 90 (93%)
Period 2 (n = 235) Pd (n = 98) Pd
BMQ
Necessitya 20.5 (20.0–21.5) \0.001 20.5 (20.0–22.5) 0.78
Concerna 10.5 (10.0–12.0) \0.001 11.0 (10.0–13.0) 0.002
Necessity-concernb 10.0 (8.0–11.0) \0.001 10.0 (6.5–11.5) 0.16
Overusec 11.0 (10.0–12.5) \0.001 10.3 (9.5–12.0) 0.002
Harmc 9.5 (8.5–11.0) 0.01 9.0 (8.0–10.5) 0.78
MEMS
Days with data 127 (124–127) 127 (125–127)
Adherence 96.5% (85.8–98.4%) 0.006 92.5% (80.3–98.0%) \0.001
VL
\100 copies/ml 174 (74%) 94 (96%)
Numbers show median (IQR) or n(%)
BMQ beliefs in medicine questionnaire, MEMS medication event monitoring system adherence, Viral load
\100 copies/ml
a Range 5–25, midpoint 15
b Range -20–20, midpoint 0
c Range 4–20, midpoint 12
d Wilcoxon paired signed rank test comparing periods 1 and 2 in children with measurements at both
timepoints (216 naı¨ve, 86 experienced)
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response after 1 year on treatment, among those treatment
naı¨ve at enrolment. The harm and overuse scales, however,
did show that caregivers held some concerns that they were
prepared to express. Despite this, the high levels of
adherence measured by MEMS caps indicated that these
beliefs did not impede treatment given by caregivers, at
least not to levels associated with substantially lower odds
of viral suppression. To our knowledge, this is the only
paediatric study conducted in sub-Saharan Africa using the
BMQ to help understand children’s caregiver’s beliefs
about medicines and linking them to children’s adherence
and treatment outcomes.
One of the limitations of the study was that responses to
the BMQ were less variable than might have been expec-
ted. The most frequent score in the necessity scale was 20,
occurring when carers expressed agreement with all five
questions. The lack of variability reduced ability to detect
associations, and should be taken into account when
interpreting the results. Another limitation is that the study
population is from a clinical trial setting, where caregivers
may be more highly motivated than in routine healthcare.
The negative effects on MEMS adherence observed in
Period 2 among ART naı¨ve children whose carers believed
in divine healing suggest that this represents a real problem
that needs to be addressed. Similarly large negative effects
on adherence were associated with reporting of side-ef-
fects, although these associations did not reach even mar-
ginal statistical significance. Interestingly, no effect was
seen in the ART experienced, again suggesting that this
was a selected group where these issues did not present a
problem. An observational study conducted in Uganda
reported patients have discontinued ART due to belief in
spiritual healing [23]. Therefore discussing caregiver’s
beliefs/practices with reference to ART for their children
may promote good adherence and avert those who may
consider divine healing as quick fix to long term treatment.
Given the fact that the BMQ is a set of simple self-
reported questions, the fact that any BMQ constructs were
associated with the objective endpoint of viral load sup-
pression is interesting and important. This study suggests
that the BMQ necessity and necessity-concerns scores may
be a good proxy for predicting adherence among children.
Table 3 Univariate associations of baseline characteristics with BMQ and MEMS (linear regression), and viral suppression\100 copies/ml
(logistic regression) BMQ at week 0, 6 or 24, MEMS adherence to week 18, Viral load at week 48
BMQ (necessity-concern) MEMS VL
b 95% CI p b 95% CI p b 95% CI p
Naive at enrolment
Age (yrs) -0.09 (-0.26–0.08) 0.28 0.45 (-0.12–1.01) 0.12 1.22 (1.04–1.44) 0.01
Sex (female) 0.21 (-0.48 to 0.89) 0.55 0.71 (-1.57–2.99) 0.54 1.86 (1.10–3.15) 0.02
Main carer (mother) -0.65 (-1.42v0.12) 0.10 1.04 (-1.55–3.63) 0.43 1.20 (0.67–2.13) 0.54
WHO stage  0.74 (0.06–1.41) 0.03 -0.79 (-3.06–1.48) 0.49 1.32 (0.79–2.21) 0.29
CD4% 0.07 (0.04–0.10) <0.01 -0.10 (-0.21–0.01) 0.07 1.01 (0.99–1.04) 0.39
WAZ -0.19 (-0.42 to 0.03) 0.09 0.80 (0.06–1.55) 0.03 1.24 (1.05–1.47) 0.01
Centrea <0.01 0.71
Lubowa 0.13 (-0.75 to 1.02) 5.74 (2.74–8.74) 0.73 (0.36–1.49)
Baylor -1.50 (-2.43 to -0.57) 3.94 (0.79–7.09) 0.86 (0.40–1.84)
Gulu 1.06 (-0.01 to 2.12) 0.11 (-3.48–3.71) 0.64 (0.27–1.47)
Experienced at enrolment
Age (yrs) 0.23 (-0.09 to 0.54) 0.16 -0.78 (-1.81–0.24) 0.13 0.92 (0.62–1.38) 0.70
Sex (female) -0.12 (-1.26 to 1.03) 0.84 1.21 (-2.50–4.91) 0.52 2.61 (0.48–14.2) 0.27
Main carer (mother) 21.61 (22.73 to20.48) 0.01 -0.32 (-4.13–3.49) 0.87 1.18 (0.25–5.58) 0.84
WHO stage  0.35 (-0.79 to 1.50) 0.54 -1.43 (-5.15–2.29) 0.45 0.18 (0.02–1.57) 0.12
CD4% 0.01 (-0.06 to 0.09) 0.73 0.22 (-0.02–0.46) 0.07 0.99 (0.89–1.09) 0.78
WAZ -0.28 (-0.84 to 0.29) 0.33 -1.20 (-3.02–0.63) 0.20 0.66 (0.28–1.53) 0.33
Centrea 0.05 0.33 b
Lubowa 0.16 (-1.28 to 1.60) 3.54 (-1.23–8.31)
Baylor -1.42 (-2.70 to -0.14) 0.78 (-3.47–5.02)
Associations statistically significant at the 5 % level shown in bold
a Reference centre is UTH, Zambia
b Model not fitted due to empty cells
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Whilst we did not find negative associations between
concerns about overuse and adherence, only negative
associations between concerns and viral load suppression,
it is well recognised that even MEMS is an imperfect
measure of adherence, and that caregivers may open bottles
but still not give the entire dose. It is certainly possible that
occasionally not giving the whole dose might be more
likely to occur among caregivers with concerns about
overuse, and that this could influence viral load suppres-
sion. We found that the BMQ was very easy to administer
to children’s caregivers. While our use was in a clinical
trial setting it could be used at any level of health care,
including primary health facilities and community settings.
Therefore this tool could complement adherence tools
already used within different health facilities, helping to
identify caregivers who may benefit from more intensive
follow up. Further, the fact that we identified different
components of the BMQ were more strongly associated
with early versus later viral load suppression in children
initiating ART provides some indication as to how to target
information provision more effectively at different stages
on ART.
Conclusion
We observed high levels of adherence to ART, particularly
among children whose caregiver’s beliefs in necessity of
treatment most strongly outweighed their concern. This
study suggests that the BMQ could be a valuable tool in
routine clinical practice, and that it remains important to
allay concerns about overuse of medication and to ensure
Table 4 Association between
MEMS data andBMQ scores,
adjusted for baseline
characteristics
Naive at enrolment Experienced at enrolment
Diff 95 % CI p Diff 95 % CI p
Period 1 (n = 271) (n = 97)
BMQ
Necessity-concern 0.33 (0.12–0.54) 0.002 0.04 (-0.31–0.39) 0.83
Necessity 0.45 (0.05–0.84) 0.03 0.64 (0.04–1.23) 0.04
Concern 20.30 (20.55 to 20.05) 0.02 0.23 (-0.17–0.63) 0.26
Harm 0.04 (-0.39–0.46) 0.86 -0.10 (-0.79–0.59) 0.78
Overuse 0.28 (-0.11–0.67) 0.15 0.01 (-0.57–0.60) 0.96
Side effects -0.84 (-1.80–0.13) 0.09 1.09 (-0.63–2.80) 0.21
Divine healing 0.06 (-1.18–1.29) 0.93 -0.79 (-2.58–1.01) 0.39
Period 2 (n = 235) (n = 98)
BMQ
Necessity-concern 0.50 (0.06–0.94) 0.03 -0.16 (-0.74–0.41) 0.57
Necessity 1.17 (0.17–2.17) 0.02 -0.05 (-1.32–1.22) 0.93
Concern -0.40 (-0.94–0.14) 0.15 0.27 (-0.49–1.03) 0.48
Harm -0.74 (-1.58–0.09) 0.08 0.49 (-0.68–1.67) 0.40
Overuse -0.63 (-1.37–0.12) 0.10 0.30 (-0.86–1.46) 0.61
Side effects -2.78 (-6.61–1.05) 0.15 0.39 (-4.14–4.92) 0.86
Divine healing 23.73 (26.50 to 20.97) 0.008 -1.50 (-5.21–2.21) 0.42
Associations statistically significant at the 5 % level shown in bold
Change in MEMS adherence associated with a 1-point higher BMQ score
Table 5 Association between
MEMS data and viral load
suppression\100 copies/ml,
adjusted for baseline
characteristics
Naive at enrolment Experienced at enrolment
OR 95 % CI p OR 95 % CI p
Period 1 (n = 271) (n = 97)
MEMs adherence (per 1 % higher) 1.03 (1.0–1.06) 0.07 0.96 (0.87–1.07) 0.49
Period 2 (n = 235)
(n = 98)
MEMs adherence (per 1 % higher) 1.05 (1.01–1.08) 0.006 1.03 (0.94–1.12) 0.56
Associations statistically significant at the 5 % level shown in bold
Change in odds of viral suppression associated with a 1 % increase in MEMS
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that caregivers are well informed about the long-term
necessity of ART.
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